May 25, 2026: Aligned visible freshness, meta dateModified, schema, and retatrutide hub routing. Status unchanged: no approval and no NDA filed.
May 23, 2026: Integrated TRIUMPH-1 Phase 3 obesity readout (28.3% at 80 weeks on 12 mg, 30.3% at 104 weeks in BMI ≥35 extension, dose curve 4 / 9 / 12 mg = 19.0% / 25.9% / 28.3%, discontinuation curve 4.1% / 6.9% / 11.3% vs 4.9% placebo, dysesthesia up to 12.5% on 12 mg, UTIs). Synced JSON-LD FAQPage and visible body.
April 29, 2026: Added Phase 3 clinical trial context section, expanded keyword coverage on double-blind design and metabolic-health endpoints, refreshed title for 2026 trial scope.
April 2, 2026: Audit compliance review and formatting update.
Initial publication.
TL;DR — Verdict
This is a comprehensive dosage FAQ covering the 15 most frequently asked questions about retatrutide dosing protocols. Answers are based on Phase 3 trial data from TRIUMPH-1 (pivotal obesity, May 21, 2026), TRIUMPH-4 (December 2025), and TRANSCEND-T2D-1 (March 2026). Topics include the recommended starting dose (2 mg weekly), the standard 4-week titration schedule (2 mg → 4 mg → 6 mg → 9 mg → 12 mg), the TRIUMPH-1 dose-by-dose efficacy curve (19.0% / 25.9% / 28.3% at 4 / 9 / 12 mg at 80 weeks; 30.3% at 104 weeks in the BMI ≥35 extension), pen click calculations for the 30 mg multi-dose pen, missed dose protocols, storage requirements, and how retatrutide dosing compares to semaglutide. For the full compound route through trials, approval status, dosing, and Dubai availability, use the retatrutide research hub. Researchers in the Emirates sourcing material for these protocols can check Retatrutide UAE formats for the current pen formats and pricing. For Research Use Only.
Retatrutide (LY-3437943) is a first-in-class triple hormone receptor agonist activating the GLP-1, GIP, and glucagon receptors simultaneously. It is administered as a once-weekly subcutaneous injection using a pre-filled multi-dose pen. As retatrutide advances through the TRIUMPH Phase 3 clinical program, dosing questions are among the most common inquiries from the research community. This FAQ compiles the 15 most frequently asked dosage questions, with answers grounded in published Phase 2 data (Jastreboff et al., NEJM 2023), TRIUMPH-1 topline results (May 21, 2026), TRIUMPH-4 topline results (December 2025), and TRANSCEND-T2D-1 topline results (March 2026). TRIUMPH-1 reported 28.3% mean weight loss at 80 weeks on 12 mg (rising to 30.3% at 104 weeks in the BMI ≥35 extension), a clean dose curve of 19.0% / 25.9% / 28.3% across the 4 / 9 / 12 mg arms, and a discontinuation-due-to-AE curve of 4.1% / 6.9% / 11.3% versus 4.9% placebo. Retatrutide is an investigational research compound not yet approved by any regulatory authority and Lilly has not filed an NDA as of May 25, 2026. For Research Use Only.
Phase 3 Clinical Trial Context
Why the 2026 dosing record matters
The dosing protocols summarised in this FAQ come from double-blind, randomised, placebo-controlled Phase 3 trials run by Eli Lilly across the TRIUMPH (obesity) and TRANSCEND (type 2 diabetes) programs. Three readouts set the dosing record researchers reference today:
TRIUMPH-1 (May 21, 2026): Pivotal obesity Phase 3 trial in adults with obesity and no type 2 diabetes. The trial tested the 4 / 9 / 12 mg dose arms on the standard slow-titration ladder. At 80 weeks the dose-by-dose efficacy was 19.0% / 25.9% / 28.3%, with 45.3% of 12 mg participants achieving ≥30% weight loss. The BMI ≥35 extension reached 30.3% at 104 weeks. Discontinuation due to adverse events was 4.1% / 6.9% / 11.3% across 4 / 9 / 12 mg vs 4.9% placebo, and new Phase 3 safety findings included dysesthesia up to 12.5% on 12 mg and UTIs. Full data will be presented at the ADA Scientific Sessions in June 2026.
TRIUMPH-4 (December 2025): 48-week obesity trial in adults with obesity or overweight and knee osteoarthritis using the standard 2 mg → 4 mg → 6 mg → 9 mg → 12 mg slow-titration schedule. Primary endpoint was percent change in body weight versus placebo. The double-blind design ensured neither participants nor investigators knew which arm received active compound.
TRANSCEND-T2D-1 (March 2026): Type 2 diabetes trial assessing A1C reduction and effects on blood sugar levels in addition to weight change. Dosing followed the same 4-week titration steps as TRIUMPH-4. Results extended the metabolic-health profile from obesity-only outcomes to glycaemic control, energy use, and lipid markers.
Regulatory bodies — the U.S. FDA in particular — review these double-blind data sets to set the dosing labels that will accompany any future approval. Dosing schedules used in research today closely mirror the Phase 3 protocol so that downstream data is comparable to the registrational record. Track the full Phase 3 readout calendar in our TRIUMPH trial tracker, and see formal approval status in the retatrutide approval tracker.
Getting Started
Questions 1–5 — Basics of Retatrutide Dosing
Q1: What is the recommended starting dose of retatrutide?
In the double-blind Phase 3 clinical trials (TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1), retatrutide was initiated at 2 mg once weekly by subcutaneous injection. This low starting dose was specifically selected to minimise gastrointestinal side effects during the initial adaptation period before titration to higher doses. Phase 2 data demonstrated that cohorts starting at 2 mg experienced 30–50% lower nausea rates compared to those starting at 4 mg.[1] The TRIUMPH-1 readout (May 21, 2026) confirmed dose-dependent discontinuation due to adverse events of 4.1% / 6.9% / 11.3% across the 4 / 9 / 12 mg arms versus 4.9% on placebo, validating the slow-titration design.
Q2: How is retatrutide administered?
Retatrutide is administered as a once-weekly subcutaneous injection using a pre-filled multi-dose pen. The injection is typically given in the abdomen, thigh, or upper arm. Injection sites should be rotated each week to reduce the risk of local reactions such as mild erythema or induration, which were reported at low rates in clinical trials.
Each click on the 30 mg retatrutide pen delivers 0.1 mg. Therefore, 10 clicks = 1 mg, 20 clicks = 2 mg (starting dose), 40 clicks = 4 mg, 80 clicks = 8 mg, and 120 clicks = 12 mg (maximum dose). Use the retatrutide dosage calculator for precise click counts at any dose level, including fractional doses used during custom titration protocols. For the complete dose-to-click chart including split-injection thresholds, see the pen clicks guide.
Q5: Is retatrutide taken daily or weekly?
Retatrutide is taken once weekly. The compound’s pharmacokinetic profile supports a 7-day dosing interval, with steady-state plasma concentrations maintained throughout the week. In clinical trials, participants administered their dose on the same day each week to maintain consistent drug levels.
Titration & Dose Adjustment
Questions 6–10 — Escalation, Side Effects, and Missed Doses
Q6: What does the retatrutide titration schedule look like?
The Phase 3 titration protocol starts at 2 mg weekly for 4 weeks, then escalates by one dose level every 4 weeks: 2 mg → 4 mg → 6 mg → 9 mg → 12 mg. Each 4-week period allows gastrointestinal adaptation, lets the body recalibrate energy use, and stabilises blood sugar levels before the next increase. TRIUMPH-1 also reported a separate 9 mg dose arm (efficacy 25.9% at 80 weeks, between the 4 mg 19.0% and 12 mg 28.3% arms) as part of its dose-finding Phase 3 design. The stepwise escalation design was informed by Phase 2 data showing that rapid titration nearly doubled nausea rates at equivalent doses. For complete titration tables with week-by-week click counts, see our retatrutide dosage guide.
Q7: How long does it take to reach the maximum dose?
Using the standard 4-week titration schedule (2 mg → 4 mg → 6 mg → 9 mg → 12 mg), it takes approximately 16 weeks (4 months) to reach the maximum 12 mg maintenance dose. This timeline was validated in TRIUMPH-4 and confirmed in TRIUMPH-1 (May 21, 2026), where the slow-titration ladder produced manageable discontinuation rates of 11.3% on 12 mg versus 4.9% on placebo.[1] For detailed titration timelines, see the dosage guide.
Q8: What if I experience side effects during dose escalation?
In clinical trial protocols, participants who experienced significant gastrointestinal side effects could remain at their current dose level for an additional 4 weeks before escalating. This extended adaptation period was the primary tolerability strategy used in the TRIUMPH program. Some participants in Phase 2 also had their dose reduced by one level temporarily before re-escalating. The TRIUMPH-1 Phase 3 readout (May 21, 2026) surfaced new adverse events worth tracking beyond classic GI tolerability: dysesthesia up to 12.5% on 12 mg and UTIs. For detailed adverse event rates by dose, see our retatrutide side effects article.
Q9: Did the trial protocols allow skipping a titration step?
Trial protocols did not allow skipping titration steps, based on the escalation data. Phase 2 rapid-escalation cohorts that started at higher doses experienced substantially higher nausea rates—the 8 mg rapid-start group had approximately 60% nausea compared to ~33% with slow titration to the same dose.[1] The titration protocol exists specifically to reduce adverse event severity and minimise early discontinuation.
Q10: How were missed doses handled in the trial protocols?
In clinical trial protocols, if a dose was missed, participants were generally instructed to administer it as soon as possible within 3–4 days of the scheduled date. If more than 4 days had passed, the missed dose was skipped and the next scheduled dose was taken on the regular dosing day. Double doses were not administered to compensate for a missed dose.
Questions 11–15 — Pen Duration, Storage, and Comparisons
Weekly Dose
Clicks per Dose
Doses per Pen
Pen Duration
2 mg
20
15
15 weeks
4 mg
40
7
7 weeks
8 mg
80
3
3 weeks
12 mg
120
2
2.5 weeks
Note: Pen duration is calculated for the 30 mg / 300-click pen format. At the 12 mg maintenance dose, each pen provides 2 full doses plus a partial third dose (300 ÷ 120 = 2.5). Use the dosage calculator for exact pen counts across your full protocol.
Q11: How long does one 30 mg pen last?
Pen duration depends entirely on weekly dose. At the 2 mg starting dose, one 30 mg pen lasts 15 weeks (300 clicks ÷ 20 clicks/dose = 15 doses). At the 12 mg maximum dose, one pen lasts approximately 2.5 weeks (300 ÷ 120 = 2.5 doses). During titration, pen consumption increases progressively as the dose escalates. The dosage calculator provides exact pen duration at any dose level.
Q12: How many pens do I need for a full protocol?
A full 48-week protocol (matching the Phase 2 trial duration) at the maximum 12 mg dose requires approximately 16–19 pens, depending on titration speed. The 16-week titration phase uses less compound per week than the maintenance phase. The 32-week maintenance period at 12 mg consumes approximately 12–13 pens alone. For precise pen counts at any protocol length and dose, use the dosage calculator.
Q13: How do I store the retatrutide pen?
Retatrutide pens should be stored refrigerated at 2–8°C (36–46°F) and protected from direct light at all times — before and after first use. The pen should never be frozen. Allow brief equilibration to room temperature during use only, then return it to 2–8°C refrigeration; do not store at room temperature, avoid heat above 30°C, and remove the needle between uses.
Q14: What is the difference between retatrutide and semaglutide dosing?
Both are administered once weekly via subcutaneous injection, but they differ in dose range, titration speed, and Phase 3 efficacy. Semaglutide (Wegovy) titrates from 0.25 mg to 2.4 mg over 16–20 weeks and reported 16.9% mean weight loss at 68 weeks in STEP 1. Retatrutide titrates from 2 mg to 12 mg over 16 weeks and reported 28.3% mean weight loss at 80 weeks on 12 mg in the pivotal TRIUMPH-1 Phase 3 obesity trial (May 21, 2026), rising to 30.3% at 104 weeks in the BMI ≥35 extension. Retatrutide’s higher absolute doses reflect its different receptor-binding profile as a triple agonist (GLP-1 + GIP + glucagon) versus semaglutide’s single GLP-1 pathway. For a full mechanism and efficacy comparison, see our retatrutide dosage comparison analysis.
Q15: Can I use a dosage calculator for retatrutide?
Yes. The Remy Peptides dosage calculator converts any target dose into exact pen click counts, calculates pen duration at each dose level, and estimates total pens needed for a complete research protocol. It is calibrated for the 30 mg / 300-click pen format and supports custom titration schedules.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
The Remy Peptides Editorial Board reviews research articles covering GLP-1 receptor agonists, triple agonists, and the obesity drug pipeline. Its review spans peptide analytical chemistry, HPLC purity validation, and clinical trial data interpretation.
Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
Eli Lilly and Company. Lilly’s retatrutide (LY-3437943) met primary endpoint in TRIUMPH-4 Phase 3 obesity trial. Press release, December 11, 2025.
Eli Lilly and Company. Lilly announces positive topline results from TRANSCEND-T2D-1 Phase 3 trial of retatrutide in type 2 diabetes. Press release, March 19, 2026.
Eli Lilly. TRIUMPH Clinical Trial Program for Retatrutide — Phase 3 Design. ClinicalTrials.gov.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered powerful weight loss in TRIUMPH-1 Phase 3 obesity trial. May 21, 2026. investor.lilly.com
tctMD. Retatrutide Achieves Large Weight Decreases in Patients Without Diabetes: TRIUMPH-1. May 2026. tctmd.com
AJMC. Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial. May 2026. ajmc.com